Department of Medicine

Clinical Pharmacology

Friday Journal Club (2017)


Journal Club meets on Fridays from 9:00 a.m. - 10:00 a.m. in Conference Room 300B located in R3, 3rd Floor.

2018 Schedule2017 Schedule | 2016 Schedule | 2015 Schedule | 2014 Schedule | 2013 Schedule | 2012 Schedule | 2011 Schedule | 2010 Schedule | 2009 Schedule | 2008 Schedule | 2007 Schedule

                          Date                                          Faculty                                              Fellow/PhD      Student     Title / Journal 
January 27 Sara Quinney Kimberly Burgess

Identification of microRNA Biomarker Candidates in Urine and Plasma from Rats with Kidney of Liver Damage 

DOI 10.1002/jat.3358

February 3 Tom Callaghan Brandon Gufford

Zombie - Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York. 

N Engl J Med 2017;376:235-42. DOI: 10.1056/NEJMoa1610300

February 17 Ken Levy Ingrid Ferreira Metzger

Clinical inpact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients:  A prospective pilot randomized controlled trial. 

PLOS ONE | DOI:10.1371/journal.pone.0170905

March 3 David Jones Violeta Rodriguez Romero

Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy:  a randomised, double-blind, placebo-controlled, phase 3 study. 

Lancet Diabetes Endocrinol 2016; 4: 211–20  DOI 10.1016/S2213-8587(15)00417-9

March 17 No Journal Club - ASCPT    
April 7 Eric Benson Abdullah Assiri

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. 

Theranostics 2017, Vol. 7, Issue 2  doi: 10.7150/thno.16767

April 21 Jim Tisdale Marelize Swart

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer  A Randomized Cllinical Trial 

JAMA. 2017;317(1):37-47 DOI 10.1000/jama.2016.18305

May 5 No Journal Club    
May 19 Brian Decker Cathy Fulton

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease 

DOI: 10.1056/NEJMoa1615664

June 2 David Haas Tom DeLuca

Modelling of the cancer cell cycle as a tool for rational drug development:  A systems pharmacology approach to cyclotherapy 

PLoS Comput Biol 13(5): e1005529  DOI 10.1371/journal.pcbi.1005529

June 16 Todd Skaar Tyler Shugg

Common Genetic Variant Risk Score is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk  A Pilot Study 

Circulation. 2017;135:1300–1310 DOI: 10.1161/CIRCULATIONAHA.116.023980

August 18 Zeruesenay Desta Ingrid Ferreira Metzger

Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

N Engl J Med 2017;377:233-45.  DOI: 10.1056/NEJMoa1615822

September 1 Brandon Gufford Alicia Teagarden

Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Serverely Obese Versus Nonobese Critically III Septic Patients and the Risk of Under- and Overdosing

Online Clinical Investigations  DOI: 10.1097/CCM.0000000000002287

September 15 Rich Bergstrom Cathy Fulton

Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial

Annals of Clinical and Translational Neurology 2017; 4(7): 491–505 doi: 10.1002/acn3.424

October 6 David Haas Elena Tomaselli

Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative
Mechanistic Modeling Study


October 20 Cancelled  



November 3 No Journal Club - Symposium    
November 17 Sara Quinney Kimberly Burgess

Lack of Bioequivalence Among Low-dose, Enteric-coated Aspirin Preparations

Clinical Pharmacology & Therapeutics doi:10.1002/cpt.874

December 1 Tom Callaghan Katie Hargreaves and Stephanie Liu

Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy

Neurology® 2016;86:890–897

December 15 David Jones Tom DeLuca

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

Clinical Pharmacology DOI: 10.1002/jcph.821